## AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A method for treating users having systemic inflammation by reducing highly sensitive C- reactive protein levels in the body of a user which comprises:

administering in liquid form as a single dose composition, on a daily basis for a period of at least about 2 days, a composition ~~selected from the group~~ consisting essentially of:

(a) from about 1 to about 20 milligrams of a leukotriene inhibitor,

(b) from about 150 to about 250 milligrams of an antihistamine,

(c) from about 110 µcg to about 220 µcg of a corticosteroid and,

(d) mixtures thereof

to reduce highly sensitive C-reactive protein in the body of the user.

2. **(Canceled)**

3. **(Previously Amended)** The method of claim 1 wherein the selected composition is used in an amount of:

(a) from about 5 to about 15 milligrams of the leukotriene inhibitor,

(b) from about 175 to about 200 milligrams of the antihistamine, and

(c) from about 110 µcg to about 220µcg of the corticosteroid.

4. **(Previously Amended)** The method of claim 1 wherein the leukotriene inhibitor is selected from the group consisting of:

zafirlukast, zileuton and mixtures thereof.

5. **(Previously Amended)** The method of claim 1 wherein the antihistamine is selected from the group consisting of:

cetirizine, fexofenadine, loratadine, and azelastine.

6. **(Previously Amended)** The method of claim 1 wherein the corticosteroid is selected from the group consisting of:

mometasone furoate monohydrate, triamcinalone, acetonide, and budesonide.

7. **(Previously Amended)** The method of claim 1 wherein:

(a) the leukotriene inhibitor is montelukast sodium,

(b) the antihistamine is cetirizine, and

(c) the steroid is fluticasone propionate.

8. **(Previously Amended)** The method of claim 1 wherein the composition comprises:

(a) the leukotriene inhibitor,

(b) the antihistamine, and

(c) the corticosteroid.

9. **(Cancelled)**